Axon Neuroscience is a clinical-stage biotechnology leader pioneering tau-targeted therapies to prevent and treat Alzheimer’s disease and related neurodegenerative disorders.

Founded in 1999 by Prof. Michal Novak, who discovered the tau protein as a key cause of Alzheimer’s disease, Axon has built the world’s largest dedicated tau research team with over 20 senior in-house scientists advancing cutting-edge programs from discovery to clinical development.

Axon’s lead candidate, AADvac1, is the most clinically advanced active vaccine targeting pathological tau. In the successful Phase II ADAMANT study, AADvac1 showed excellent safety and immunogenicity, with over 80% of patients developing strong anti-tau antibodies. Axon demonstrated consistent biomarker efficacy across NfL, GFAP, and MRI volumetry, alongside a trending clinical benefit — validating its disease-modifying potential.

Building on this foundation, Axon is advancing AADvac1 into two major international platform trials starting in 2026:

The Alzheimer’s Tau Platform (ATP) enrolling 375 patients with early Alzheimer’s, evaluating AADvac1 alone and in combination with anti-amyloid antibodies.

The Progressive Supranuclear Palsy (PSP) Phase II Platform Trial, enrolling 220 patients, expanding AADvac1’s potential across tauopathies beyond Alzheimer’s.

Axon’s diversified pipeline also includes a humanized anti-tau monoclonal antibody (AADvac2), and small-molecule programs targeting tau aggregation and propagation.

With over two decades of pioneering science and consistent clinical validation, Axon Neuroscience is transforming the future of brain health with the promise of first-in-class, disease-modifying therapies for millions suffering worldwide.

AXON Neuroscience

Org chart

Teams

Offices